JP2024023610A - Composition containing vitamin B12s - Google Patents
Composition containing vitamin B12s Download PDFInfo
- Publication number
- JP2024023610A JP2024023610A JP2023207968A JP2023207968A JP2024023610A JP 2024023610 A JP2024023610 A JP 2024023610A JP 2023207968 A JP2023207968 A JP 2023207968A JP 2023207968 A JP2023207968 A JP 2023207968A JP 2024023610 A JP2024023610 A JP 2024023610A
- Authority
- JP
- Japan
- Prior art keywords
- vitamin
- weight
- fatty acid
- composition
- sorbitan fatty
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 71
- FEZWOUWWJOYMLT-DSRCUDDDSA-M cobalt;[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,1 Chemical compound [Co].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FEZWOUWWJOYMLT-DSRCUDDDSA-M 0.000 title abstract description 18
- -1 fatty acid ester Chemical class 0.000 claims abstract description 37
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 27
- 239000000194 fatty acid Substances 0.000 claims abstract description 27
- 229930195729 fatty acid Natural products 0.000 claims abstract description 27
- 229920001214 Polysorbate 60 Polymers 0.000 claims abstract description 24
- FDJOLVPMNUYSCM-UVKKECPRSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7, Chemical compound [Co+3].N#[C-].C1([C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)[N-]\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O FDJOLVPMNUYSCM-UVKKECPRSA-L 0.000 claims description 60
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 40
- 229930003427 Vitamin E Natural products 0.000 claims description 17
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 17
- 239000011709 vitamin E Substances 0.000 claims description 17
- 229940046009 vitamin E Drugs 0.000 claims description 17
- 235000019165 vitamin E Nutrition 0.000 claims description 17
- 239000011715 vitamin B12 Substances 0.000 claims description 14
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims 2
- 238000000354 decomposition reaction Methods 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 3
- 238000010586 diagram Methods 0.000 abstract 1
- RMRCNWBMXRMIRW-BYFNXCQMSA-M cyanocobalamin Chemical compound N#C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O RMRCNWBMXRMIRW-BYFNXCQMSA-M 0.000 description 29
- 239000000047 product Substances 0.000 description 21
- 235000000639 cyanocobalamin Nutrition 0.000 description 17
- 239000011666 cyanocobalamin Substances 0.000 description 17
- 229960002104 cyanocobalamin Drugs 0.000 description 17
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 13
- 239000003814 drug Substances 0.000 description 9
- 239000002537 cosmetic Substances 0.000 description 8
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 8
- 229920000053 polysorbate 80 Polymers 0.000 description 8
- 239000002738 chelating agent Substances 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 7
- 229940068968 polysorbate 80 Drugs 0.000 description 7
- 150000005846 sugar alcohols Polymers 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229930003799 tocopherol Natural products 0.000 description 6
- 239000011732 tocopherol Substances 0.000 description 6
- 229960001295 tocopherol Drugs 0.000 description 6
- 235000010384 tocopherol Nutrition 0.000 description 6
- 125000002235 cyanocobalamin group Chemical group 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 5
- 238000002845 discoloration Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000000551 dentifrice Substances 0.000 description 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 229940042585 tocopherol acetate Drugs 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000005977 Ethylene Substances 0.000 description 2
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 229920001213 Polysorbate 20 Polymers 0.000 description 2
- 229920001219 Polysorbate 40 Polymers 0.000 description 2
- 229920002651 Polysorbate 85 Polymers 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- YOZNUFWCRFCGIH-BYFNXCQMSA-L hydroxocobalamin Chemical compound O[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O YOZNUFWCRFCGIH-BYFNXCQMSA-L 0.000 description 2
- 235000015110 jellies Nutrition 0.000 description 2
- 229940049918 linoleate Drugs 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
- 229940113171 polysorbate 85 Drugs 0.000 description 2
- 159000000001 potassium salts Chemical class 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 235000014214 soft drink Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 229930003802 tocotrienol Natural products 0.000 description 2
- 239000011731 tocotrienol Substances 0.000 description 2
- 235000019148 tocotrienols Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 235000019156 vitamin B Nutrition 0.000 description 2
- 239000011720 vitamin B Substances 0.000 description 2
- 229940045999 vitamin b 12 Drugs 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- DEKFZWMENCCOFU-LIKAHPKFSA-N 2-[(2r)-2-[(2r,3s,4r)-3,4-bis(2-hydroxyethoxy)oxolan-2-yl]-2-(2-hydroxyethoxy)ethoxy]ethyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCOC[C@@H](OCCO)[C@H]1OC[C@@H](OCCO)[C@@H]1OCCO DEKFZWMENCCOFU-LIKAHPKFSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- XPFCZYUVICHKDS-UHFFFAOYSA-N 3-methylbutane-1,3-diol Chemical compound CC(C)(O)CCO XPFCZYUVICHKDS-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010002065 Anaemia megaloblastic Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000242722 Cestoda Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- IELOKBJPULMYRW-NJQVLOCASA-N D-alpha-Tocopheryl Acid Succinate Chemical compound OC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C IELOKBJPULMYRW-NJQVLOCASA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 208000000682 Megaloblastic Anemia Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 208000031845 Pernicious anaemia Diseases 0.000 description 1
- 229920002642 Polysorbate 65 Polymers 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- MSCCTZZBYHQMQJ-AZAGJHQNSA-N Tocopheryl nicotinate Chemical compound C([C@@](OC1=C(C)C=2C)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC1=C(C)C=2OC(=O)C1=CC=CN=C1 MSCCTZZBYHQMQJ-AZAGJHQNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- WBSXYJYELWQLCJ-UHFFFAOYSA-K cobalt(3+);[5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] 1-[3-[2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2,7,12,17-tetrahydro-1h-corrin-21-id-3-yl]propanoylamino]propan-2 Chemical compound O.[OH-].[Co+3].OCC1OC(N2C3=CC(C)=C(C)C=C3N=C2)C(O)C1OP([O-])(=O)OC(C)CNC(=O)CCC1(C)C(CC(N)=O)C2[N-]\C1=C(C)/C(C(C\1(C)C)CCC(N)=O)=N/C/1=C\C(C(C/1(CC(N)=O)C)CCC(N)=O)=N\C\1=C(C)/C1=NC2(C)C(C)(CC(N)=O)C1CCC(N)=O WBSXYJYELWQLCJ-UHFFFAOYSA-K 0.000 description 1
- 239000011789 cobamamide Substances 0.000 description 1
- ZIHHMGTYZOSFRC-UWWAPWIJSA-M cobamamide Chemical compound C1(/[C@](C)(CCC(=O)NC[C@H](C)OP(O)(=O)OC2[C@H]([C@H](O[C@@H]2CO)N2C3=CC(C)=C(C)C=C3N=C2)O)[C@@H](CC(N)=O)[C@]2(N1[Co+]C[C@@H]1[C@H]([C@@H](O)[C@@H](O1)N1C3=NC=NC(N)=C3N=C1)O)[H])=C(C)\C([C@H](C/1(C)C)CCC(N)=O)=N\C\1=C/C([C@H]([C@@]\1(CC(N)=O)C)CCC(N)=O)=N/C/1=C(C)\C1=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]1CCC(N)=O ZIHHMGTYZOSFRC-UWWAPWIJSA-M 0.000 description 1
- 235000006279 cobamamide Nutrition 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 229940099418 d- alpha-tocopherol succinate Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000036654 deficiency anemia Diseases 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940009662 edetate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-MDZDMXLPSA-N elaidic acid Chemical compound CCCCCCCC\C=C\CCCCCCCC(O)=O ZQPPMHVWECSIRJ-MDZDMXLPSA-N 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- IIRDTKBZINWQAW-UHFFFAOYSA-N hexaethylene glycol Chemical compound OCCOCCOCCOCCOCCOCCO IIRDTKBZINWQAW-UHFFFAOYSA-N 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000011704 hydroxocobalamin Substances 0.000 description 1
- 235000004867 hydroxocobalamin Nutrition 0.000 description 1
- 229960001103 hydroxocobalamin Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 231100001016 megaloblastic anemia Toxicity 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000014593 oils and fats Nutrition 0.000 description 1
- 229940041667 oral paste Drugs 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 229940102545 peg-20 sorbitan isostearate Drugs 0.000 description 1
- 229930015698 phenylpropene Natural products 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000176 photostabilization Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 description 1
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
- 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 229940101027 polysorbate 40 Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940099511 polysorbate 65 Drugs 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 235000014102 seafood Nutrition 0.000 description 1
- 235000012046 side dish Nutrition 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 229940037001 sodium edetate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 239000001589 sorbitan tristearate Substances 0.000 description 1
- 235000011078 sorbitan tristearate Nutrition 0.000 description 1
- 229960004129 sorbitan tristearate Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000008054 sulfonate salts Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 150000003611 tocopherol derivatives Chemical class 0.000 description 1
- 229950009883 tocopheryl nicotinate Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 229940034610 toothpaste Drugs 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 150000003712 vitamin E derivatives Chemical class 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
【課題】本発明の目的は、ビタミンＢ12類を含み、光暴露によるビタミンＢ12類の分解が抑制されている組成物を提供することである。【解決手段】ビタミンＢ12類を含む組成物にポリオキシエチレンソルビタン脂肪酸エステルを含有させ、且つビタミンＢ12類１重量部に対してポリオキシエチレンソルビタン脂肪酸エステルが１０重量部以下となるように設定することにより、過酷な条件で光暴露を行ってもビタミンＢ12類の分解を抑制でき、ビタミンＢ12類に対する光安定化効果が格段顕著に奏される。【選択図】なしAn object of the present invention is to provide a composition containing vitamin B12s, in which decomposition of vitamin B12s due to exposure to light is suppressed. [Solution] Polyoxyethylene sorbitan fatty acid ester is contained in a composition containing vitamin B12s, and the amount of polyoxyethylene sorbitan fatty acid ester is set to be 10 parts by weight or less per 1 part by weight of vitamin B12s. As a result, decomposition of vitamin B12s can be suppressed even when exposed to light under harsh conditions, and the photostabilizing effect on vitamin B12s is significantly enhanced. [Selection diagram] None
Description
本発明は、ビタミンＢ12類を含み、光暴露によるビタミンＢ12類の分解が抑制されている組成物に関する。 The present invention relates to a composition containing vitamin B 12 , in which decomposition of vitamin B 12 due to exposure to light is suppressed.
ビタミンＢ12類は、水溶性ビタミンの一種であり、生命を維持するために不可欠な栄養素である。ビタミンＢ12類は、ビタミンＢ12類欠乏症、巨赤芽球性貧血、広節裂頭条虫症、悪性貧血、吸収不全症候群、眼精疲労、栄養性貧血、妊娠性貧血、神経痛等の症状の予防又は改善、肌荒れ改善等に有効であることが知られており、飲食品、口腔ケア製品、医薬品、化粧料等で使用されている。一方、ビタミンＢ12類は、光暴露により分解され易いことが知られており、ビタミンＢ12類を含む製品を実用化する上では、ビタミンＢ12類に対して光安定性を備えさせることが不可欠になっている。 Vitamin B12 is a type of water-soluble vitamin and is an essential nutrient for sustaining life. Vitamin B12 is associated with symptoms such as vitamin B12 deficiency, megaloblastic anemia, tapeworm disease, pernicious anemia, malabsorption syndrome, eye strain, nutritional anemia, pregnancy anemia, and neuralgia. It is known to be effective in preventing or improving skin irritation and improving rough skin, and is used in foods and drinks, oral care products, pharmaceuticals, cosmetics, etc. On the other hand, it is known that vitamin B 12 types are easily degraded by exposure to light, and in order to put products containing vitamin B 12 types into practical use, it is necessary to provide photostability to vitamin B 12 types. It has become essential.
従来、ビタミンＢ12類に光安定性を備えさせる製剤技術について種々報告されている。例えば、特許文献１には、ビタミンＢ12、及びブタノールを含む製剤が、ビタミンＢ12に光安定性を付与できることが開示されている。また、特許文献２には、ビタミンＢ12、及び特定のフェニルプロペンカルボニル構造を有するビタミン安定剤を含むビタミン組成物が、ビタミンＢ12に光安定性を付与できることが開示されている。また、特許文献３には、ビタミンＢ12にシクロデキストリン又はその誘導体を添加することによって、ビタミンＢ12に光安定化が図られることが開示されている。 Conventionally, various formulation techniques for imparting photostability to vitamin B12 have been reported. For example, Patent Document 1 discloses that a preparation containing vitamin B 12 and butanol can impart photostability to vitamin B 12 . Furthermore, Patent Document 2 discloses that a vitamin composition containing vitamin B 12 and a vitamin stabilizer having a specific phenylpropene carbonyl structure can impart photostability to vitamin B 12 . Furthermore, Patent Document 3 discloses that photostabilization of vitamin B 12 can be achieved by adding cyclodextrin or a derivative thereof to vitamin B 12 .
このように、従来、ビタミンＢ12類の光安定化を図る製剤技術については検討されているものの、近年、製品の多様化や品質向上に対する要望が向上しており、このような要望に追従するために、ビタミンＢ12類の光安定化を図る新たな技術の開発が望まれている。 As described above, although formulation technology for photostabilizing vitamin B12 has been studied in the past, in recent years there has been an increasing demand for product diversification and quality improvement, and it is necessary to follow these demands. Therefore, it is desired to develop a new technology for photostabilizing vitamin B12 .
本発明の目的は、ビタミンＢ12類を含み、光暴露によるビタミンＢ12類の分解が抑制されている組成物を提供することである。 An object of the present invention is to provide a composition containing vitamin B 12 and in which decomposition of vitamin B 12 due to exposure to light is suppressed.
本発明者は、前記課題を解決すべく鋭意検討を行ったところ、ビタミンＢ12類を含む組成物にポリオキシエチレンソルビタン脂肪酸エステルを含有させ、且つビタミンＢ12類１重量部に対してポリオキシエチレンソルビタン脂肪酸エステルが１０重量部以下となるように設定することにより、過酷な条件で光暴露を行ってもビタミンＢ12類の分解を抑制でき、ビタミンＢ12類に対する光安定化効果が格段顕著に奏されることを見出した。本発明は、かかる知見に基づいて、更に検討を重ねることにより完成したものである。 The present inventor conducted extensive studies to solve the above problems, and found that polyoxyethylene sorbitan fatty acid ester was added to a composition containing vitamin B 12s , and polyoxyethylene sorbitan was added to a composition containing 1 part by weight of vitamin B 12s . By setting the amount of ethylene sorbitan fatty acid ester to 10 parts by weight or less, it is possible to suppress the decomposition of vitamin B 12 types even when exposed to light under harsh conditions, and the photostabilizing effect on vitamin B 12 types is extremely remarkable. I discovered that it can be played. The present invention was completed through further studies based on this knowledge.
即ち、本発明は、下記に掲げる態様の発明を提供する。
項１． ビタミンＢ12類及びポリオキシエチレンソルビタン脂肪酸エステルを含有し、且つビタミンＢ12類１重量部当たりポリオキシエチレンソルビタン脂肪酸エステルが１０重量部以下である、ビタミンＢ12類含有組成物。
項２． 更にビタミンＥ類を含有する、項１に記載のビタミンＢ12類含有組成物。
項３． ビタミンＢ12類１重量部当たりビタミンＥ類が０．００１２５～１０００重量部である、項２に記載のビタミンＢ12類含有組成物。
項４． 水性組成物である、項１～３のいずれかに記載のビタミンＢ12類含有組成物。
That is, the present invention provides the inventions of the following aspects.
Item 1. A vitamin B 12 -containing composition, which contains vitamin B 12 and polyoxyethylene sorbitan fatty acid ester, and the polyoxyethylene sorbitan fatty acid ester is 10 parts by weight or less per 1 part by weight of vitamin B 12 .
Item 2. Item 1. The vitamin B 12 -containing composition according to item 1, which further contains vitamin E.
Item 3. Item 2. The vitamin B 12 -containing composition according to item 2, wherein the vitamin E content is 0.00125 to 1000 parts by weight per 1 part by weight of vitamin B 12 classes.
Item 4. Item 4. The vitamin B 12 -containing composition according to any one of Items 1 to 3, which is an aqueous composition.
本発明によれば、光暴露によるビタミンＢ12類の分解を抑制できるので、ビタミンＢ12類を含む各種製品の保存安定性を向上させることが可能になる。 According to the present invention, it is possible to suppress the decomposition of vitamin B 12s due to exposure to light, thereby making it possible to improve the storage stability of various products containing vitamin B 12s .
１．ビタミンＢ 12 類含有組成物
本発明のビタミンＢ12類含有組成物は、ビタミンＢ12類及びポリオキシエチレンソルビタン脂肪酸エステルを含有し、且つビタミンＢ12類１重量部当たりポリオキシエチレンソルビタン脂肪酸エステルが１０重量部以下であることを特徴とする。以下、本発明のビタミンＢ12類含有組成物について、詳述する。
1. Composition containing vitamin B 12s The composition containing vitamin B 12s of the present invention contains vitamin B 12s and polyoxyethylene sorbitan fatty acid ester, and contains polyoxyethylene sorbitan fatty acid ester per part by weight of vitamin B 12s . It is characterized by being 10 parts by weight or less. The vitamin B 12 -containing composition of the present invention will be described in detail below.
［ビタミンＢ12類］
ビタミンＢ12類とは、ビタミンＢ12（シアノコバラミン）、その誘導体、及びそれらの塩を指す。本発明で使用されるビタミンＢ12類の種類については、飲食品、口腔ケア製品、医薬品、化粧料等の製品に配合可能であることを限度として特に制限されない。例えば、ビタミンＢ12の誘導体としては、メチルコバラミン、ヒドロキソコバラミン、アデノシルコバラミン、アクアコバラミン等が挙げられる。また、ビタミンＢ12及びその誘導体の塩としては、例えば、酢酸塩、トリフルオロ酢酸塩、酪酸塩、パルミチン酸塩、ステアリン酸塩、フマル酸塩、マレイン酸塩、コハク酸塩、マロン酸塩、乳酸塩、酒石酸塩、クエン酸塩等のカルボン酸塩；メタンスルホン酸塩、トルエンスルホン酸塩、トシル酸塩等の有機スルホン酸塩；塩酸塩、硫酸塩、硝酸塩、リン酸塩等の無機酸塩；メチルアミン、トリエチルアミン、トリエタノールアミン等の有機アミン塩；ナトリウム塩、カリウム塩等のアルカリ金属塩；カルシウム、マグネシウム等のアルカリ土類金属塩；アンモニウム塩等が挙げられる。
[Vitamin B 12 types]
Vitamin B 12 refers to vitamin B 12 (cyanocobalamin), its derivatives, and salts thereof. The type of vitamin B12 used in the present invention is not particularly limited as long as it can be incorporated into products such as food and drink products, oral care products, pharmaceuticals, and cosmetics. For example, derivatives of vitamin B12 include methylcobalamin, hydroxocobalamin, adenosylcobalamin, aquacobalamin, and the like. Salts of vitamin B12 and its derivatives include, for example, acetate, trifluoroacetate, butyrate, palmitate, stearate, fumarate, maleate, succinate, malonate, Carboxylate salts such as lactate, tartrate, and citrate; Organic sulfonate salts such as methanesulfonate, toluenesulfonate, and tosylate; Inorganic acids such as hydrochloride, sulfate, nitrate, and phosphate Salts; organic amine salts such as methylamine, triethylamine, triethanolamine; alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium and magnesium salts; ammonium salts and the like.
これらのビタミンＢ12類は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These 12 types of vitamin B may be used alone or in combination of two or more.
これらのビタミンＢ12類の中でも、好ましくはシアノコバラミンが挙げられる。 Among these vitamin B12s , cyanocobalamin is preferred.
本発明のビタミンＢ12類含有組成物におけるビタミンＢ12類の濃度については、当該ビタミンＢ12類含有組成物の形状や製品形態等に応じて適宜設定すればよいが、例えば、０．０００１～０．２重量％、好ましくは０．０００２～０．０２重量％、より好ましくは０．０００２～０．００２重量％が挙げられる。 The concentration of vitamin B 12 types in the vitamin B 12 type-containing composition of the present invention may be set as appropriate depending on the shape and product form of the vitamin B 12 type-containing composition, but for example, from 0.0001 to 0.2% by weight, preferably 0.0002 to 0.02% by weight, more preferably 0.0002 to 0.002% by weight.
［ポリオキシエチレンソルビタン脂肪酸エステル］
本発明のビタミンＢ12類含有組成物は、ビタミンＢ12類の光安定化を図るために、ビタミンＢ12類１重量部に対して１０重量部以下となる比率でポリオキシエチレンソルビタン脂肪酸エステルを含有する。
[Polyoxyethylene sorbitan fatty acid ester]
The vitamin B 12 -containing composition of the present invention contains polyoxyethylene sorbitan fatty acid ester at a ratio of 10 parts by weight or less per 1 part by weight of vitamin B 12 in order to photostabilize the vitamin B 12. contains.
ポリオキシエチレンソルビタン脂肪酸エステルとは、脂肪酸とソルビタンとのモノエステル、ジエステル、又はトリエステルであるソルビタン脂肪酸エステルにエチレンオキサイドが縮合している化合物である。ポリオキシエチレンソルビタン脂肪酸エステルを構成する脂肪酸の炭素数としては、例えば、８～３０、好ましくは１０～２２、より好ましくは１２～１８が挙げられる。また、ポリオキシエチレンソルビタン脂肪酸エステルに縮合されているエチレンオキサイドの平均付加モル数としては、例えば、６～１６０、好ましくは６～６０、より好ましくは６～３０が挙げられる。ポリオキシエチレンソルビタン脂肪酸エステルとしては、具体的には、ポリソルベート２０（ポリオキシエチレン（２０）ソルビタンモノパルミテート）、ポリソルベート４０（ポリオキシエチレン（２０）ソルビタンモノラウレート）、ポリソルベート６０（ポリオキシエチレン（２０）ソルビタンモノステアレート）、ポリソルベート６５（ポリオキシエチレン（２０）ソルビタントリステアレート）、ポリソルベート８０（ポリオキシエチレン（２０）ソルビタンモノオレエート）、ポリソルベート８５（ポリオキシエチレン（２０）ソルビタントリオレエート）、ステアリン酸ＰＥＧ－６ソルビタン、イソステアリン酸ＰＥＧ－２０ソルビタン、オレイン酸ＰＥＧ－６ソルビタン、ポリソルベート８５等が挙げられる。 Polyoxyethylene sorbitan fatty acid ester is a compound in which ethylene oxide is condensed with sorbitan fatty acid ester, which is a monoester, diester, or triester of fatty acid and sorbitan. The number of carbon atoms in the fatty acid constituting the polyoxyethylene sorbitan fatty acid ester is, for example, 8 to 30, preferably 10 to 22, more preferably 12 to 18. Further, the average number of moles of ethylene oxide added to the polyoxyethylene sorbitan fatty acid ester is, for example, 6 to 160, preferably 6 to 60, more preferably 6 to 30. Specifically, polyoxyethylene sorbitan fatty acid esters include polysorbate 20 (polyoxyethylene (20) sorbitan monopalmitate), polysorbate 40 (polyoxyethylene (20) sorbitan monolaurate), polysorbate 60 (polyoxyethylene (20) sorbitan monostearate), polysorbate 65 (polyoxyethylene (20) sorbitan tristearate), polysorbate 80 (polyoxyethylene (20) sorbitan monooleate), polysorbate 85 (polyoxyethylene (20) sorbitan trioleate) ate), PEG-6 sorbitan stearate, PEG-20 sorbitan isostearate, PEG-6 sorbitan oleate, polysorbate 85, and the like.
これらのポリオキシエチレンソルビタン脂肪酸エステルは、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These polyoxyethylene sorbitan fatty acid esters may be used alone or in combination of two or more.
これらのポリオキシエチレンソルビタン脂肪酸エステルの中でも、より一層効果的にビタミンＢ12類の光安定化を図るという観点から、好ましくはポリソルベート８０が挙げられる。 Among these polyoxyethylene sorbitan fatty acid esters, polysorbate 80 is preferred from the viewpoint of more effectively photostabilizing vitamin B12s .
本発明のビタミンＢ12類含有組成物において、ビタミンＢ12類とポリオキシエチレンソルビタン脂肪酸エステルとを共存させる際の両者の比率としては、ビタミンＢ12類１００重量部当たり、ポリオキシエチレンソルビタン脂肪酸エステルが１０重量部以下であればよいが、好ましくは１～１０重量部、より好ましくは２．５～１０重量部が挙げられる。 In the vitamin B 12 -containing composition of the present invention, when vitamin B 12 and polyoxyethylene sorbitan fatty acid ester are allowed to coexist, the ratio of both is per 100 parts by weight of vitamin B 12 , polyoxyethylene sorbitan fatty acid ester. The amount may be 10 parts by weight or less, preferably 1 to 10 parts by weight, more preferably 2.5 to 10 parts by weight.
また、本発明のビタミンＢ12類含有組成物におけるポリオキシエチレンソルビタン脂肪酸エステルの濃度については、前記比率を充足する範囲で適宜設定すればよいが、例えば、０．００１～０．１重量％、好ましくは０．００２５～０．１重量％、より好ましくは０．００５～０．１重量％が挙げられる。 Further, the concentration of polyoxyethylene sorbitan fatty acid ester in the vitamin B 12 -containing composition of the present invention may be appropriately set within a range that satisfies the above ratio, but for example, 0.001 to 0.1% by weight, Preferably it is 0.0025 to 0.1% by weight, more preferably 0.005 to 0.1% by weight.
［ビタミンＥ類］
本発明のビタミンＢ12類含有組成物には、ビタミンＢ12類及びポリオキシエチレンソルビタン脂肪酸エステルに加えてビタミンＥ類を含有していてもよい。このようにビタミンＥ類を更に含有させることにより、より一層効果的にビタミンＢ12類の光安定化を図ることが可能になる。
[Vitamin E]
The vitamin B 12 -containing composition of the present invention may contain vitamin E in addition to vitamin B 12 and polyoxyethylene sorbitan fatty acid ester. By further containing vitamin E in this way, it becomes possible to further effectively photostabilize vitamin B12 .
ビタミンＥ類とは、ビタミンＥ（トコフェロール、トコトリエノール）、及びその誘導体を指す。本発明で使用されるビタミンＥ類の種類については、飲食品、口腔ケア製品、医薬品、化粧料等の製品に配合可能であることを限度として特に制限されない。例えば、トコフェロール及びトコトリエノールは、α－、β－、γ－、及びδ－のいずれであってもよく、またｄ体又はｄｌ体のいずれであってもよい。また、例えば、ビタミンＥの誘導体としては、酢酸トコフェロール、コハク酸トコフェロール、リノール酸トコフェロール、リノレイン酸トコフェロール、ニコチン酸トコフェロール、（リノール酸／オレイン酸）トコフェロール等のトコフェロール有機酸エステル等が挙げられる。 Vitamin E refers to vitamin E (tocopherol, tocotrienol) and its derivatives. The type of vitamin E used in the present invention is not particularly limited as long as it can be incorporated into products such as food and drink products, oral care products, pharmaceuticals, and cosmetics. For example, tocopherol and tocotrienol may be any of α-, β-, γ-, and δ-, and may be either d-form or dl-form. Further, examples of derivatives of vitamin E include tocopherol organic acid esters such as tocopherol acetate, tocopherol succinate, tocopherol linoleate, tocopherol linoleate, tocopherol nicotinate, and tocopherol (linoleic acid/oleic acid).
これらのビタミンＥ類は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。 These vitamin E types may be used alone or in combination of two or more types.
これらのビタミンＥ類の中でも、より一層効果的にビタミンＢ12類の光安定化を図るという観点から、好ましくはトコフェロールの誘導体、より好ましくはトコフェロール酢酸エステルが挙げられる。 Among these vitamin E types, preferred are tocopherol derivatives, more preferably tocopherol acetate, from the viewpoint of more effectively photostabilizing vitamin B 12 types.
本発明のビタミンＢ12類含有組成物にビタミンＥ類を含有させる場合、ビタミンＢ12類とビタミンＥ類との比率としては、例えば、ビタミンＢ12類１重量部当たり、ビタミンＥ類が０．００１２５～１０００重量部、好ましくは０．０２５～２５０重量部、より好ましくは２．５～２５０重量部が挙げられる。 When vitamin E is contained in the vitamin B 12 -containing composition of the present invention, the ratio of vitamin B 12 to vitamin E is, for example, 0.00% of vitamin E per 1 part by weight of vitamin B 12 . 00125 to 1000 parts by weight, preferably 0.025 to 250 parts by weight, more preferably 2.5 to 250 parts by weight.
また、本発明のビタミンＢ12類含有組成物にビタミンＥ類を含有させる場合、ビタミンＢ12類含有組成物におけるビタミンＥ類の濃度としては、例えば、０．０００２５～０．１重量％、好ましくは０．０００５～０．０５重量％、より好ましくは０．０００５～０．００５重量％が挙げられる。 Further, when vitamin E is contained in the vitamin B 12 -containing composition of the present invention, the concentration of vitamin E in the vitamin B 12 -containing composition is, for example, 0.00025 to 0.1% by weight, preferably is 0.0005 to 0.05% by weight, more preferably 0.0005 to 0.005% by weight.
［キレート剤］
本発明のビタミンＢ12類含有組成物は、更にキレート剤を含有してもよい。本発明で使用されるキレート剤の種類については、飲食品、口腔ケア製品、医薬品、化粧料等の製品に配合可能であることを限度として特に制限されないが、例えば、エデト酸、クエン酸、コハク酸、及びこれら塩等が挙げられる。塩の形態としては、例えば、ナトリウム塩、カリウム塩等のアルカリ金属塩等が挙げられる。これらのキレート剤は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。
[Chelating agent]
The vitamin B12 -containing composition of the present invention may further contain a chelating agent. The type of chelating agent used in the present invention is not particularly limited as long as it can be incorporated into products such as food and beverages, oral care products, pharmaceuticals, and cosmetics, but examples include edetic acid, citric acid, and succinic acid. Examples include acids and salts thereof. Examples of the salt form include alkali metal salts such as sodium salts and potassium salts. These chelating agents may be used alone or in combination of two or more.
これらのキレート剤の中でも、好ましくはエデト酸及びその塩、より好ましくはエデト酸ナトリウムが挙げられる。 Among these chelating agents, edetate and its salts are preferred, and sodium edetate is more preferred.
また、本発明のビタミンＢ12類含有組成物においてキレート剤を含有させる場合、ビタミンＢ12類含有組成物におけるキレート剤の濃度については、特に制限されないが、例えば、０．００１～０．３重量％、好ましくは０．００５～０．１重量％、より好ましくは０．０１～０．１重量％が挙げられる。 Further, when a chelating agent is contained in the vitamin B 12 -containing composition of the present invention, the concentration of the chelating agent in the vitamin B 12 -containing composition is not particularly limited, but for example, 0.001 to 0.3 weight %, preferably 0.005 to 0.1% by weight, more preferably 0.01 to 0.1% by weight.
［多価アルコール］
本発明のビタミンＢ12類含有組成物は、更に多価アルコールを含有してもよい。本発明で使用される多価アルコールの種類としては、例えば、エチレングリコール、１，３－ブチレングリコール、プロピレングリコール、イソプレングリコール、ジエチレングリコール、ジプロピレングリコール、ポリプロピレングリコール、グリセリン等が挙げられる。これらの多価アルコールは、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。
[Polyhydric alcohol]
The vitamin B 12 -containing composition of the present invention may further contain a polyhydric alcohol. Examples of the polyhydric alcohol used in the present invention include ethylene glycol, 1,3-butylene glycol, propylene glycol, isoprene glycol, diethylene glycol, dipropylene glycol, polypropylene glycol, and glycerin. These polyhydric alcohols may be used alone or in combination of two or more.
これらの多価アルコールの中でも、好ましくプロピレングリコールが挙げられる。 Among these polyhydric alcohols, propylene glycol is preferred.
また、本発明のビタミンＢ12類含有組成物に多価アルコールを含有させる場合、ビタミンＢ12類含有組成物における多価アルコールの濃度については、特に制限されないが、例えば、０．０１～１０重量％、好ましくは０．１～５重量％、より好ましくは０．１～１重量％が挙げられる。 Further, when a polyhydric alcohol is contained in the composition containing vitamin B 12s of the present invention, the concentration of the polyhydric alcohol in the composition containing vitamins B 12s is not particularly limited, but for example, 0.01 to 10% by weight. %, preferably 0.1 to 5% by weight, more preferably 0.1 to 1% by weight.
［その他の成分］
本発明のビタミンＢ12類含有組成物には、前記成分の他に、当該ビタミンＢ12類含有組成物の形状や製品形態に応じて、各種の薬理成分、食品素材、添加剤等の成分を含有させてもよい。このような成分は、ビタミンＢ12類含有組成物の形状や製品形態に応じて使用可能なものを適宜選定すればよいが、例えば、水、薬理成分、清涼化剤、界面活性剤（ポリオキシエチレンソルビタン脂肪酸エステル以外）、油脂類、ロウ類、炭化水素類、脂肪酸類、高級アルコール類、エステル類、水溶性高分子、金属石鹸、１価低級アルコール類、ｐＨ調整剤、緩衝剤、酸化防止剤、紫外線防止剤、防腐剤、香料、粉体、増粘剤、色素等が挙げられる。これらの成分は、１種単独で使用してもよく、また２種以上を組み合わせて使用してもよい。これらの成分の濃度については、使用する成分の種類や組成物の形状及び製品形態等に応じて適宜設定される。
[Other ingredients]
In addition to the above-mentioned components, the vitamin B 12 -containing composition of the present invention may contain various pharmacological ingredients, food materials, additives, etc. depending on the shape and product form of the vitamin B 12-containing composition. It may be included. Such ingredients may be appropriately selected depending on the shape and product form of the vitamin B12 -containing composition, but examples include water, pharmacological ingredients, cooling agents, surfactants (polyoxygen (other than ethylene sorbitan fatty acid ester), oils and fats, waxes, hydrocarbons, fatty acids, higher alcohols, esters, water-soluble polymers, metal soaps, monovalent lower alcohols, pH adjusters, buffers, antioxidants agents, ultraviolet inhibitors, preservatives, fragrances, powders, thickeners, pigments, etc. These components may be used alone or in combination of two or more. The concentrations of these components are appropriately set depending on the types of components used, the shape of the composition, the product form, and the like.
［ビタミンＢ12類含有組成物の形状・製品形態等］
本発明のビタミンＢ12類含有組成物は、水性組成物又は非水性組成物のいずれであってもよい。一般的にビタミンＢ12類は水性組成物中で光暴露により分解され易くなる傾向があるが、本発明によれば、水性組成物中でも光暴露によるビタミンＢ12類の分解を効果的に抑制できる。このような本発明の効果を鑑みると、本発明のビタミンＢ12類含有組成物の好適な例として水性組成物が挙げられる。
[Shape, product form, etc. of vitamin B 12 -containing composition]
The vitamin B 12 -containing composition of the present invention may be either an aqueous composition or a non-aqueous composition. Generally, vitamin B 12 types tend to be easily decomposed by light exposure in an aqueous composition, but according to the present invention, the decomposition of vitamin B 12 types due to light exposure can be effectively suppressed even in an aqueous composition. . In view of the effects of the present invention, an aqueous composition is a preferred example of the vitamin B12 -containing composition of the present invention.
水性組成物とは、水を含有する組成物である。水性組成物における水の濃度としては、具体的には、５０量％以上、好ましくは５０～９９．９９重量％、より好ましくは５０～９９．８重量％が挙げられる。水性組成物の形状としては、例えば、液状、ゲル状、ペースト状等が挙げられる。 An aqueous composition is a composition containing water. Specifically, the concentration of water in the aqueous composition is 50% by weight or more, preferably 50 to 99.99% by weight, more preferably 50 to 99.8% by weight. Examples of the shape of the aqueous composition include liquid, gel, and paste.
ビタミンＢ12類含有組成物が水性組成物である場合、そのｐＨとしては、例えば、４．０～８．０、好ましくは５．０～７．７、より好ましくは５．５～７．０が挙げられる。 When the vitamin B 12 -containing composition is an aqueous composition, the pH thereof is, for example, 4.0 to 8.0, preferably 5.0 to 7.7, more preferably 5.5 to 7.0. can be mentioned.
また、非水性組成物とは、配合成分の吸湿によって不可避的に含まれる水を除いて、水が実質的に配合されていない組成物である。非水性組成物の形状としては、例えば、粉末状、顆粒状、錠剤状、丸剤状、軟膏状等が挙げられる。 Furthermore, a non-aqueous composition is a composition in which substantially no water is blended, except for water that is inevitably included due to moisture absorption of the blended components. Examples of the shape of the non-aqueous composition include powder, granule, tablet, pill, ointment, and the like.
本発明のビタミンＢ12類含有組成物の製品形態については、特に制限されず、例えば、飲食品、口腔ケア製品、医薬品、化粧料等が挙げられる。 The product form of the vitamin B 12 -containing composition of the present invention is not particularly limited, and examples thereof include foods and drinks, oral care products, pharmaceuticals, cosmetics, and the like.
飲食品としては、例えば、清涼飲料水、酒類、栄養ドリンク、コーヒー、茶、牛乳、果汁飲料、清涼飲料等の飲料；錠剤、顆粒剤、粉剤、ゼリー剤、散剤、懸濁剤、シロップ剤、カプセル剤（ソフトカプセル剤、ハードカプセル剤）等のサプリメント；チーズ、ウインナー、ソーセージ、ハム、魚介加工品等の副菜；アイスクリーム、クッキー、ケーキ、ゼリー、プリン、キャンディー、チューインガム、ヨーグルト、グミ、チョコレート、ビスケット等の菓子類等が挙げられる。 Foods and drinks include, for example, soft drinks, alcoholic beverages, energy drinks, coffee, tea, milk, fruit juice drinks, soft drinks, and other beverages; tablets, granules, powders, jellies, powders, suspensions, syrups, Supplements such as capsules (soft capsules, hard capsules); Side dishes such as cheese, sausages, sausages, ham, processed seafood products; Ice cream, cookies, cakes, jelly, puddings, candies, chewing gum, yogurt, gummies, chocolate, Examples include confectionery such as biscuits.
口腔ケア製品としては、例えば、練歯磨剤、粉歯磨剤、液体歯磨剤等の歯磨剤；歯用クリーム；マウスウォッシュ、含嗽剤等の洗口剤；口腔用パスタ剤、マウススプレー、口腔内崩壊性フィルム、ゲル、トローチ、タブレット、チュアブル、口腔用軟膏剤等が挙げられる。 Examples of oral care products include dentifrices such as toothpaste, powdered dentifrice, and liquid dentifrice; dental creams; mouth washes such as mouthwashes and gargles; oral paste preparations, mouth sprays, and oral disintegrations. Examples include sex films, gels, troches, tablets, chewables, and oral ointments.
医薬品としては、例えば、散剤、顆粒剤、錠剤、カプセル剤、丸剤、液剤等の内服用の医薬品；輸液、注射剤等の皮下、血管内又は腹腔内投与用の医薬品；液剤（ローション剤、スプレー剤、エアゾール剤、及び乳液剤を含む）、水溶性軟膏剤、油脂性軟膏剤、クリーム剤、フォーム剤、ジェル剤、貼付剤、点眼剤、洗眼剤等の皮膚又は粘膜用の医薬品等が挙げられる。 Pharmaceuticals include, for example, medicines for internal use such as powders, granules, tablets, capsules, pills, and liquids; medicines for subcutaneous, intravascular, or intraperitoneal administration such as infusions and injections; liquids (lotions, lotions, etc.); (including sprays, aerosols, and emulsions), water-soluble ointments, oil-based ointments, creams, foams, gels, patches, eye drops, eye washes, and other pharmaceuticals for the skin or mucous membranes. Can be mentioned.
化粧料としては、例えば、軟膏、クリーム、乳液、化粧水、ローション、パック、ゲル等の基礎化粧料；ファンデーション、アイシャドウ、口紅、頬紅等のメークアップ化粧料等が挙げられる。 Examples of cosmetics include basic cosmetics such as ointments, creams, emulsions, lotions, lotions, packs, and gels; makeup cosmetics such as foundations, eye shadows, lipsticks, and blushes.
以下に実施例を示して本発明をより具体的に説明するが、本発明はこれらに限定されるものではない。 EXAMPLES The present invention will be explained in more detail with reference to Examples below, but the present invention is not limited thereto.
試験例１
表１に示す組成の水性組成物を調製した。５００ｍｌ容の透明容器（ポリエチレンテレフタレート製）に得られた水性組成物５００ｍｌを充填し、昼間に直射日光が当たる室内（南側の窓から１０ｃｍ離れた場所）に３５日間静置した。３５日間の静置後に、水性組成物の外観を目視にて観察し、以下の判定基準に従って、シアノコバラミンの保存安定性を判定した。なお、シアノコバラミンはピンク色の色調を呈し、分解されると退色するため、本試験において、退色が多い程、シアノコバラミンの分解が進んでいることを示している。
＜シアノコバラミンの保存安定性＞
◎ ：製造直後に比べて、色調が同等である。
○ ：製造直後に比べて、僅かに退色が認められるが許容範囲内である。
× ：製造直後に比べて、明らかに退色が認められ許容できない。
××：退色が著しく、ほぼ無色になっている。
Test example 1
An aqueous composition having the composition shown in Table 1 was prepared. A 500 ml transparent container (made of polyethylene terephthalate) was filled with 500 ml of the obtained aqueous composition, and left for 35 days in a room exposed to direct sunlight during the day (at a distance of 10 cm from a south window). After standing still for 35 days, the appearance of the aqueous composition was visually observed, and the storage stability of cyanocobalamin was determined according to the following criteria. Note that cyanocobalamin exhibits a pink tone and discolors when decomposed, so in this test, the greater the discoloration, the more advanced the decomposition of cyanocobalamin is.
<Storage stability of cyanocobalamin>
◎: The color tone is the same as that immediately after production.
○: Slight discoloration is observed compared to immediately after production, but within an acceptable range.
×: Discoloration is clearly observed compared to immediately after production, and is not acceptable.
XX: Significant discoloration and almost colorless.
結果を表１に示す。この結果、水性組成物中で、シアノコバラミン及びポリソルベート８０を共存させても、シアノコバラミン１重量部当たりポリソルベート８０が１０重量部超である場合には、光暴露によるシアノコバラミンの分解を抑制できていなかった。これに対して、水性組成物中でシアノコバラミンと共にポリソルベート８０を共存させ、且つシアノコバラミン１重量部当たりポリソルベート８０が１０重量部以下の場合には、光暴露によるシアノコバラミンの分解を抑制できることが確認された。また、水性組成物中でシアノコバラミンと、シアノコバラミン１重量部当たり１０重量部以下のポリソルベート８０と共に、トコフェロール酢酸エステルを含有させた場合には、光暴露によるシアノコバラミンの分解を格段効果的に抑制できることも明らかとなった。 The results are shown in Table 1. As a result, even if cyanocobalamin and polysorbate 80 were allowed to coexist in the aqueous composition, if the amount of polysorbate 80 was more than 10 parts by weight per 1 part by weight of cyanocobalamin, the decomposition of cyanocobalamin due to light exposure could not be suppressed. On the other hand, it was confirmed that when polysorbate 80 coexists with cyanocobalamin in the aqueous composition and the amount of polysorbate 80 is 10 parts by weight or less per 1 part by weight of cyanocobalamin, the decomposition of cyanocobalamin due to light exposure can be suppressed. It is also clear that when tocopherol acetate is contained together with cyanocobalamin and 10 parts by weight or less of polysorbate 80 per 1 part by weight of cyanocobalamin in an aqueous composition, the decomposition of cyanocobalamin due to light exposure can be significantly suppressed. It became.
処方例
表２に示す組成の水性組成物を調製した。得られた水性組成物を、前記試験例１と同様の方法でシアノコバラミンの保存安定性を評価したところ、いずれも、光暴露によるシアノコバラミンの分解を効果的に抑制できていた。
Formulation Example An aqueous composition having the composition shown in Table 2 was prepared. When the obtained aqueous compositions were evaluated for storage stability of cyanocobalamin in the same manner as in Test Example 1, it was found that in all cases the decomposition of cyanocobalamin due to light exposure could be effectively suppressed.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023207968A JP2024023610A (en) | 2019-05-31 | 2023-12-08 | Composition containing vitamin B12s |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019102033A JP2020196672A (en) | 2019-05-31 | 2019-05-31 | Vitamin B12-containing composition |
| JP2023207968A JP2024023610A (en) | 2019-05-31 | 2023-12-08 | Composition containing vitamin B12s |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019102033A Division JP2020196672A (en) | 2019-05-31 | 2019-05-31 | Vitamin B12-containing composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2024023610A true JP2024023610A (en) | 2024-02-21 |
Family
ID=73552975
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019102033A Pending JP2020196672A (en) | 2019-05-31 | 2019-05-31 | Vitamin B12-containing composition |
| JP2023207968A Pending JP2024023610A (en) | 2019-05-31 | 2023-12-08 | Composition containing vitamin B12s |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019102033A Pending JP2020196672A (en) | 2019-05-31 | 2019-05-31 | Vitamin B12-containing composition |
Country Status (3)
| Country | Link |
|---|---|
| JP (2) | JP2020196672A (en) |
| CN (1) | CN113811314A (en) |
| WO (1) | WO2020241374A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7436151B2 (en) * | 2019-05-31 | 2024-02-21 | 小林製薬株式会社 | Method for photostabilizing vitamin B12s |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005154437A (en) * | 2003-11-07 | 2005-06-16 | Rohto Pharmaceut Co Ltd | Pharmaceutical composition comprising tranilast |
| JP2005247799A (en) * | 2004-03-08 | 2005-09-15 | Zeria Pharmaceut Co Ltd | Eye drop |
| JP2008100957A (en) * | 2006-10-20 | 2008-05-01 | Taisho Pharmaceutical Co Ltd | Eye drop |
| DE102007012644A1 (en) * | 2007-03-16 | 2008-09-18 | Bayer Healthcare Ag | Stabilization of vitamin B12 |
| CN101711769A (en) * | 2009-11-23 | 2010-05-26 | 北京京卫信康医药科技发展有限公司 | Stable injection composite of 12 complex vitamins and preparation method thereof |
| JP2012031184A (en) * | 2011-09-16 | 2012-02-16 | Kobayashi Pharmaceutical Co Ltd | Ophthalmic composition |
| KR20190065237A (en) * | 2016-10-07 | 2019-06-11 | 라이온 가부시키가이샤 | Ophthalmic products and methods for inhibiting viscosity lowering |
| TW201919656A (en) * | 2017-09-29 | 2019-06-01 | 日商參天製藥股份有限公司 | Stabilized cyanocobalamine-containing aqueous composition and stabilization method of cyanocobalamine characterized in that the cyanocobalamine-containing aqueous composition can maintain effectiveness for a longer period of time |
| JP7133942B2 (en) * | 2018-02-27 | 2022-09-09 | ロート製薬株式会社 | ophthalmic composition |
-
2019
- 2019-05-31 JP JP2019102033A patent/JP2020196672A/en active Pending
-
2020
- 2020-05-19 CN CN202080034923.2A patent/CN113811314A/en active Pending
- 2020-05-19 WO PCT/JP2020/019747 patent/WO2020241374A1/en active Application Filing
-
2023
- 2023-12-08 JP JP2023207968A patent/JP2024023610A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN113811314A (en) | 2021-12-17 |
| WO2020241374A1 (en) | 2020-12-03 |
| JP2020196672A (en) | 2020-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024023610A (en) | Composition containing vitamin B12s | |
| EP3581187A1 (en) | Skin pigmentation inhibitor | |
| JPWO2005108503A1 (en) | Method for suppressing fading of tar dye, and tar dye-containing composition in which fading is suppressed | |
| US11395790B2 (en) | Organic hydroperoxide reduction in perfumery raw materials | |
| KR20150081249A (en) | Oral composition | |
| JP7270465B2 (en) | Method for photostabilizing vitamin B12s | |
| JP7436151B2 (en) | Method for photostabilizing vitamin B12s | |
| EP3305757B1 (en) | 10-hydroxy-cis-12-octadecenoic acid alkyl ester and use thereof | |
| JP7368108B2 (en) | aqueous composition | |
| JP7321680B2 (en) | external composition | |
| JP6762782B2 (en) | An acidic composition with excellent stability of the folic acid contained | |
| JPS6245202B2 (en) | ||
| JP2019014672A (en) | Aqueous gel-like composition for skin whitening | |
| JP3082058B2 (en) | 6-O-α-D-galactopyranosyl-L-ascorbic acid or salt thereof, process for producing the same, and use thereof | |
| EP2452577B1 (en) | Aqueous solution of phytin and use of said solution for preparing a liquid food supplement or a cosmetic composition | |
| JP7201142B2 (en) | Folic acid-containing acidic composition with excellent stability of folic acid | |
| EP3618799A1 (en) | Organic hydroperoxide reduction in perfumery raw materials and food raw materials | |
| WO2024095311A1 (en) | Compound containing ascorbic acid derivative | |
| KR102337297B1 (en) | Cosmetic or pharmaceutical composition for skin elasticity, anti-wrinkle, or skin moisturizing comprising sophoricoside or a pharmaceutically acceptable salt thereof | |
| JPH0630746A (en) | Sterilization of food containing ascorbic acid | |
| JP7198573B2 (en) | Aqueous formulation | |
| KR20170080020A (en) | Composition for improving skin conditions comprising Lithospermic acid | |
| KR20150121492A (en) | Composition for skin cell regeneration or anti-wrinkle | |
| AU2007229399B2 (en) | Use of taurine or derivatives thereof for the treatment of alopecia | |
| KR20170080026A (en) | Composition for improving skin conditions comprising geraniin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231218 |